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INTRODUCTION 
 
Unstable angina lies in the centre of the spectrum of clinical 
condition caused by myocardial ischemia. This changes range from 
Chronic Stable Angina (CSA) to Acute Coronary Syndrome (ACS) 
.  Acute coronary syndrome consists of myocardial infarction 
associated with electrocardiographic ST segment elevation 
(STEMI) and Unstable Angina /Non ST segment elevation 
myocardial infarction (UA/ NSTEMI). STEMI1 is  associated with 
total coronary occlusion, whereas UA/ NSTEMI are usually 
associated with partial obstruction in which the lumen is not totally 
occluded. If partial occlusion is long in duration and greater in 
severity myocardial necrosis occurs and the patient is classified 
under non Q wave MI. Unstable Angina is an acute coronary 
syndrome which is not associated with myocardial necrosis.  
 
           The most common cause of UA is rupture or erosion of 
atherosclerotic plaque which superimposed by non occlusive 
thrombi. Plaque rupture is predisposed by variable factors including 
high lipid content, local inflammation causing breakdown of thin 
shoulder of plaque, coronary artery constriction, local shear stress 
factor and platelet activation. Out of which inflammation appears to 
play a key role in all the stages of atherosclerosis starting from fatty 
streak involving recruitment of leucocytes by expression of 
leukocyte adhesion molecule , migration of mononuclear cells, 
proliferation of smooth muscle cells to thrombotic complication 
involving physical disruption are associated with inflammation. It is 
not surprising that there is elevation of inflammatory markers in 
low grade inflammation and their estimation helps the prediction of 
severity of inflammation. Some of the markers include fibrinogen, 
IL-6, IL-1,adhesion molecules like ICAM-12,5, TNF, C-reactive 
protein etc.  
 
             Out of these, CRP3 levels are independently associated with 
cardiovascular disease in apparently healthy individuals and 
patients presenting with Acute Coronary Syndrome(ACS). CRP 
concentrations are higher in patients with ACS and correlate with 
number of complex lesions in these patients. These findings 
indicate that serum CRP is a marker of disease activity and this 
concept is endorsed by studies showing that CRP levels correlate 
with cardiovascular risk in ACS patients.CRP is not merely a 
marker of systemic inflammation but may also play a role in 
sustaining the inflammation in ACS. Increased serum CRP levels in 
patients with chronic Stable Angina(CSA) may be a reflection of 
ongoing inflammation7 in the atheromatous plaque, which may lead 
to plaque vulnerability and progress to acute coronary  syndromes. 
It has been recently reported that hs-CRP level correlates with the 
number of vulnerable atherosclerotic plaques with superficial foam 
cells, large necrotic cores and thin fibrous cap atheroma.These 
findings suggest that the increased risk of future coronary events 
observed in patients with elevated serum CRP is directly related to 
the increased number of vulnerable plaques prone to rupture, 
strengthening the role of the CRP as a major risk factor for the 
development of clinical manifestations of Coronary Artery 
Disease(CAD). CRP has been shown to actively participate in both 
atheromatous lesion formation and plaque disruption.   
   
     CRP increases the expression of endothelial adhesion 
molecules and monocyte chemo attractant protein-1 (MCP-1), 
facilitates native LDL uptake into macrophages4, promotes 
monocyte activation and a procoagulant effect by inducing 
monocytes to synthesize tissue factor. CRP can also activate the 
classic pathway of complement activation and has been 
demonstrated to co localize with terminal complement complexes 
in established coronary plaques. Recently, it has been reported that 
several vulnerable plaques other than the “culprit” stenosis can be 
found in individual patients with MI and that multiple plaque 
disruption occurs in patients with ACS. These findings are likely to 
be the result of a diffuse inflammatory process that leads to 
multifocal plaque instability6,53. CRP may thus be a marker of this 
process.  
 
 
         This study is the measure of the highly sensitive C - reactive 
protein (hs_CRP) values in patients who were hospitalized for 
unstable angina and to assess the outcome of these patients and also 
to correlate between the levels of hs_CRP and various risk factors 
and clinical, laboratory profile in patient with unstable angina. 
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY: 
 
1. To assess the prognostic value of hs_CRP in patients with 
unstable angina who were hospitalized. 
 
2. To correlate between the elevation of hs_CRP and the 
occurrence and the severity of recurrent coronary events 
during the hospital stay. 
 
3. To correlate between hs_CRP elevation and occurrence of 
complications in unstable angina patients during the hospital 
stay. 
 
4. To analyse  the relationship between various risk factors and 
elevation of hs- CRP levels in unstable angina patients. 
 
 
 
 
REVIEW OF LITERATURE 
   DEFINITION: 
Unstable Angina is defined as angina pectoris or equivalent 
ischemic discomfort with at least one of the three features. 
1) It occurs at rest (or with minimal exertion) usually lasting 
more than 10 minutes. 
2) It is severe and of new onset (i.e. with prior to 4 to 6 weeks) 
and/or. 
3) It occurs with crescendo pattern (i.e. distinctly more severe, 
prolonged or frequently than previously episode). 
 
 BRAUNWALD CLASSIFICATION OF UNSTABLE 
ANGINA: 
(According to characteristics of anginal pain and the underlying 
cause) 
CLASS                CHARACTERISTICS 
I                           EXERTIONAL ANGINA 
                            New onset, severe or accelerate angina .No rest 
angina in last 2  
                            Months       
II                         REST ANGINA, SUBACUTE 
    Rest angina within the last month but none within 
48 hours                                               
III                         REST ANGINA, ACUTE 
                             Rest angina within 48 hours of presentation 
                             CLINICAL CIRCUMSTANCES 
A                        SECONDARY UNSTABLE ANGINA 
                           Caused by no cardiac condition, such as anemia,                              
                           Infection, thyrotoxicosis or hypoxemia 
B                         PRIMARY UNSTABLE ANGINA 
C                        POST INFARCTION UNSTABLE ANGINA 
                           Within 2 weeks of documented myocardial 
infarction (MI). 
INTENSITY    
¾ Occurrence of unstable angina in the absence of treatment for 
chronic stable angina (CSA) 
¾ During standard treatment for chronic stable angina 
¾ Despite maximal anti-ischemic drug therapy   
 
 
ECG CHANGES 
¾ With ischemic ST/T changes during pain 
 
¾ Without ischemic ST/T changes during pain 
 
PATHOPHYSIOLOG Y OF UNSTABLE ANGINA 
 
        Unstable angina accounts for more than 1 million hospital 
admissions annually; 6 to 8 percent of patients with this condition 
have nonfatal myocardial infarction or die within the first year after 
diagnosis. Recently, the term “Acute Coronary Syndromes “has 
been used to describe the spectrum of conditions that includes 
unstable angina, non-Q-Wave myocardial infarction (which 
generally presents without ST-segment elevation), and Q-wave 
myocardial infarction (which generally presents with ST-segment 
elevation). Patients with unstable angina and those with non- Q-
wave myocardial infarction often present in a similar manner, and 
the distinction between the two conditions can be made only many 
hours or days latter, when the results of cardiac- enzyme tests 
become available.  
PATHOGENESIS 
Initiation of the Cascade of Plaque Fissure and Rupture Disruption 
of a formed plaque is a complex pathologic process that is central 
to the initiation of the acute coronary syndromes. Sudden total or 
near-total arterial occlusion frequently develops in arteries that 
previously appeared to have minimal stenosis. Two thirds of 
arteries with plaques that rupture and in which a totally occlusive 
thrombus subsequently develops have stenosis of 50 percent or less 
before plaque rupture, and in 97 percent of patients, stenosis is 
initially less than 70 percent.  The arterial lesions of patients with 
unstable angina frequently have complex, eccentric morphologic 
features on coronary angiography; such features have been found to 
represent ruptured plaque with superimposed thrombus. 
 
 Mature plaques are made up of two main components: 
 
        A lipid-rich core and a meshwork of extra cellular- matrix 
proteins that form a fibrous cap8. The presence of large, eccentric 
lipid pools and infiltration of foam cells are the characteristics of 
the lipid core most frequently associated with fissured or ruptured 
plaques. The majority of these lesions rupture at the sites of greatest 
mechanical stress, notably the junction of the plaque cap and the 
adjacent normal intima or the shoulder regions of the lipid pool. 
Fissures occurring at weak cap sites and not at sites subject to the 
greatest mechanical stresses are thought to be initiated by 
proteinases secreted by macrophages that enzymatic ally degrade 
the fibrous cap. 
 
 
 
 
Acute Thrombosis and Platelet Aggregation9,10.11 
      Local thrombosis occurring after plaque disruption results from 
complex interactions among the lipid core, smooth-muscle cells, 
macrophages, and collagen. The lipid core is the most potent 
substrate for platelet-rich thrombus formation, and both smooth-
muscle and foam cells within the core correlate with the expression 
of tissue factor in unstable plaques.  Once exposed to blood, tissue 
factor interacts with factor VIIa to initiate a cascade of enzymatic 
reactions resulting in the local generation of thrombin and 
deposition of fibrin. Because of the delicate equilibrium between 
thrombosis and endogenous thrombolysis, some acute vascular 
lesions resolve when fissures are repaired.As part of the response to 
any type of disruption of the endothelial wall, platelets aggregate 
and release granular contents that further propagate platelet 
aggregation, vasoconstriction, and thrombus formation  
         Systemic factors and inflammation also contribute to 
alterations in the hemostatic and coagulation pathways and may 
play a part in the initiation of the intermittent thrombosis that is 
characteristic of unstable angina. Inflammatory acute-phase 
reactants, cytokines, chronic infections, and catecholaminergic 
surges may provide a systemic stimulus for enhancing production 
of tissue factor, procoagulant activity, or platelet hyper agreeability. 
 
 
Coronary Vasospasm 
      Although not central to the underlying pathogenesis of the acute 
coronary syndromes, episodic vasospasm may contribute to 
vascular instability by altering preexisting coronary plaques, which 
causes intimal disruption and penetration of macrophages or 
aggregation of platelets. These processes -in turn -may lead to the 
formation of foam cells and the proliferation of smooth-muscle 
cells. 
 
 Erosion of Coronary Plaque without Rupture12 
 
An alternative mechanism of luminal narrowing may involve 
the rapid proliferation and migration of smooth-muscle cells in 
response to endothelial injury. Rapid conformational changes in the 
shape and size of a lesion due to the expansion of the smooth 
muscle may lead to the relatively abrupt onset of luminal narrowing 
and symptoms of ischemia. Current techniques cannot clearly 
distinguish between patients whose acute symptoms are due to 
conventional plaque rupture and those whose symptoms are due to 
minor erosions or conformational changes. 
 
ATHEROSCLEROSIS IS AN INFLAMMATION;13 
Inflammation has potential role in every stage of 
atherogenesis. Oxidative stress, modified lipoproteins and 
haemodynamic force cause insult to the vascular endothelium. 
Injured endothelium produces several responses like endothelial 
dysfunction, characterized by upregulation of vascular adhesions 
molecule I (VCAM-1) and intercellular adhesion molecule (ICAM 
- 1), that along with chemokines increase the adhesion of 
mononuclear leukocytes, and subsequently it migrates into the 
subendothelial space. Simultaneously there is uptake of low density 
lipoproteins (LDL) by monocyte derived macrophage and it 
transforms into lipid-laden foam cells which are the key elements 
of fatty streaks.These fatty streaks are the first recognizable 
progenitors of atherosclerotic lesion. The mononuclear cells release 
cytokines, interlukin- 1 (IL-1) and interlukin-6 (IL-6) that promote 
oxidation/ uptake of LDL, cellular recruitment & release of CRP 
from hepatocyte, it also releases mitogens that stimulate smooth 
muscle cell proliferations & maturation of fatty streak. A fibrous 
cap forms over this developing mixture of inflammatory and 
smooth muscle cells, intracellular, and extra- cellular lipids which 
eventually become recognizable as an advance complex 
atherosclerotic plaque.  
This cap composed of dense extra cellular matrix that is 
derived from type I and III collagen and elastin and forms a barrier 
between the procoagulant contents of atheroma core and circulating 
blood. Erosion or rupture of this barrier causes exposure of 
atheroma core and promotion of thrombus formation. When the 
forming thrombus leads to rapid compromise of arterial flow, acute 
myocardial ischemia or infarction may result. The extent of 
coronary stenosis does not match with the progressive risk of acute 
coronary syndrome. This discordance between the involvement of 
angiographic stenosis of  coronary arteries and the acute coronary 
syndrome has redirected the emphasis from the arterial lumen, 
visualized by angiography towards the characteristic of 
atherosclerotic lesion and the factors that influence it’s 
vulnerability to rupture. Macrophage and T lymphocyte dominate at 
the site of plaque regardless of their lesion morphology. The exact 
mechanism by which these cells cause plaque disruption, still not 
well defined but several potential links have emerged. 
Inflammatory cytokines stimulate smooth muscle cells, and 
macrophage that produce collagenase and elastase which degrade 
protective extracellular matrix.  Interferon (produced by T 
lymphocyte in atheroma core) decreases the collagen by smooth 
muscle cells. Inflammatory cells and mediators promote thrombus 
formation and vessels occlusion by modulation of platelet 
activation, coagulation cascade and vasomotor functions21,22.  
 
 
C - REACTIVE PROTEIN14,15,16 
           CRP14 is the most reliable marker of inflammation, now 
viewed as a prominent partaker in endothelial dysfunction and 
atherosclerosis. It is 1, 35,000 dalton non-immunoglobin protein, 
having five identical subunit (pentameric). C-reactive protein was 
first described by Tillet and Francis in 1930. They concluded that 
sera of patients suffering from acute infection precipitated with a 
non-proteic pneumococcus extracts called C polysaccharide in the 
presence of calcium ions. The protein that caused this reaction was 
therefore called C-reactive protein (CRP). CRP specifically 
recognizes phosphocholine, the hydrophilic part of phosphatidyl 
choline of the cell membranes, complexion of CRP to the cell wall 
activates compliment via classical pathway thus stimulate 
macrophages and other cells to undergo phagocytosis. Cytokines 
like interleukin-6 stimulate hepatocyte to preferentially produce 
positive acute phase protein. High concentration of CRP found in 
the condition listed in recent studies have proved that, 
quantification of C reactive protein is superior than cytokine 
measurement (like interleukin-6, interleukin ß1, tumor necrosis 
factors) for detecting the presence of inflammation in intensive care 
patients. The advancement in the understanding of pathophysiology 
of atherosclerotic vascular disease have come new insights 
regarding potential indicators of underlying atherosclerosis and 
cardiovascular risk. 
 
  The role of inflammation to atherogenesis has attained 
increased recognition and attention has focused on several key 
mediators and novel markers of the inflammatory process, 
including acute phase reactant, C-reactive protein. High sensitive 
assay for CRP have now been developed and able to detect mild 
elevation of CRP even within normal range. Over the last decade 
various studies proved that mild elevation of CRP and 
cardiodiovascular risk among those without apparent clinical 
cardiovascular disease and those for whom the focus is on 
secondary prevention. The data have revealed that interaction 
between baseline concentration of CRP and the efficacy of common 
pharmacological therapies in primary and secondary prevention, 
suggesting not only that it may modify the increased risk associated 
with elevated CRP but also that inflammatory markers may be 
useful in targeting preventive therapies.  
FUNCTIONS OF CRP 18,19,20 
    The function of CRP is felt to be related to its role in the 
innate immune system (Du Clos, Terry V 2000). Similar to 
immunoglobulin IgG, it activates complement, binds to Fc 
receptors and acts as an opsonin for various pathogens. Interaction 
of CRP with Fc receptors leads to the generation of 
proinflammatory cytokines that enhance inflammatory response. 
Unlike IgG, which specifically recognizes distinct antigenic 
epitopes, CRP recognizes altered self and foreign molecules based 
on pattern recognition. Thus CRP is thought to act as a surveillance 
molecule for altered self and certain pathogens. This recognition 
provides an early defence and leads to a proinflammatory signal 
and activation of the humoral, adaptive immune system.  
CRP binds to molecular groups found on a wide variety of 
bacteria and act as an opsonin. Thus a number of functions have 
been ascribed to CRP, including initiation of opsonization and 
phagocytosis and activation of complements, neutrophils, and 
monocyte-macrophage. Collectively these properties imply an 
important role for CRP in the recognition of microbial organisms 
and as an immunomodulator in the host defence. CRP may also be 
important in the recognition of necrotic tissues.   (Gershov D et al) 
         
HIGH SENSITIVE C — REACTIVE PROTEIN: A Novel 
Biochemical  
Markers and Its Role in Coronary Artery Disease23 
       CRP concentration increases in the presence of inflammation, 
infection, and tissue injury. Depending on the severity of the 
inflammatory stimulus (infection, inflammation), CRP levels can 
increase up to levels 500 times normal. The 19-hour half-life makes 
CRP easy to detect in circulation. Although the sensitivity range of 
standard CRP assays (3–200 mg/L) is adequate to evaluate 
clinically significant inflammatory processes, the tests are not 
precise enough to sense small changes in CRP levels associated 
with Cardio Vascular risk in apparently healthy individuals. As a 
result, a high sensitivity assay has been developed and is currently 
in use as highly sensitive CRP (hs-CRP). The hs_CRP assays can 
detect low-grade inflammatory activity (as low as 0.15 mg/dL) 
within the vascular system, which helps to predict the first or 
recurrent coronary events. Baseline levels of CRP are strong 
independent risk predictors of future MI, stroke, and peripheral 
vascular disease. CRP level helps to stratify risk among patients 
with acute coronary syndromes (>0.16 mg/dL confers a higher rate 
of death, acute MI, or need for revascularization). In apparently 
healthy adults, a high CRP level (>0.16 mg/dL) is predictive of 
unstable angina, MI, stroke, a higher risk of restenosis, an increase 
in the incidence of complications after percutaneous transluminal 
coronary angiography and after coronary artery bypass graft 
surgery for the subsequent 8 years24.  
Infection, hs_CRP, Coronary Risk 
Various studies proved that certain pathogens notably 
cytomegalovirus virus (CMV), Chlamydia pneumoniae, 
helicobacter pylori are associated with atherogenesis and 
development of clinically relevant CAD, perhaps via inducement of 
vascular inflammation. Zhu and colleagues25 demonstrated that a 
link between anti-CMV antibodies and high CRP level in patients 
with both an elevated CRP level and seropositivity to CMV versus 
patients with CMV seropositivity alone. This finding suggests that 
CMV contributes to atherogenesis by provoking an inflammatory 
response. Further study has confirmed that risk of angiographically 
documented CAD and the magnitude of increase in CRP levels are 
associated with an increased pathogen burden (including CMV and 
C. pneumoniae). This association emphasizes the role of the 
inflammatory response and host defense mechanism in 
atherosclerosis. 
Risk factors and markers of inflammation (Rosenson RS, 
Koenig W.26) 
Clinical 
Risk 
Factor 
 
Marker association 
 
Cigarette 
smoking 
 
 
Twofold higher concentrations CRP 
than                                                                         
 
in nonsmokers  
 
Obesity, 
overweigh 
 
Significantly higher hs_CRP levels 
than in                                                       
 
normal-weight persons 
 
 
Insulin 
resistance 
 
 
Correlates with hs_CRP and fibrinogen 
Metabolic 
syndrome 
 
 
Linear relation with CRP 
 
 
          Type II        
diabetes 
 
hs_CRP predicts development 
 
PREDICTIVE VALUE OF hs-_CRP AND ITS ADVANTAGE 
OVER THER  BIOCHEMICAL MARKERS FOR CAD. 
             Data from Physician Health Study (PHS)27 and Women’s 
Health Study (WHS)28 showed that predictive values of hs_CRP are 
significantly higher than other traditional biochemical 
cardiovascular risk markers like total cholesterol (TC), HDL-
cholesterol (HDL-C), LDLcholesterol (LDL-C) and than others 
novel markers like lipoprotein-a [Lp(a)], homocystein, 
apolipoprotein A1 and B.  
 Ridker et all27,28 studies demonstrates that hs_CRP, is the 
single strongest predictor of risk in comparison with LDL-C which 
is a lesser predictor of future risk .Furthermore, in multivariate 
analysis that accounted for CAD risk factors (obesity, hypertension 
diabetes, and family history), only hs_CRP and the ratio of TC to 
HDL-C29 had independent predictive value. In the same study of 
postmenopausal women, hs_CRP was shown to be predicting risk 
among those with LDLC value < 130mg/l, a concentration deemed 
“desirable” by the current National Cholesterol Education Program 
Guidelines for primary prevention and the study demonstrated that 
hs_CRP can identify individuals at increased risk of developing 
future coronary events who otherwise would be missed if only lipid 
measurements were used. hs_CRP: Prognostic Indicator in Acute 
Coronary Syndrome. 
Erythrocyte sedimentation rate (ESR) is more commonly 
used as a non-specific marker of disease activity. The ESR, which 
is an indirect parameter of acute phase protein changes, can be 
influenced by concentrations of fibrinogen, monoclonal proteins 
and red cell morphology, whereas CRP has no cross-interfaces. 
CRP is useful for its negative predictive value as a negative CRP 
rules out the possibility of an inflammatory or necrotic course. The 
serum CRP concentrations increase faster than that of the ESR and 
when the condition subsides, CRP falls very quickly, reaching 
normal levels several days before the ESR normalises .These  
several disadvantages prevent it from being an ideal laboratory test 
to monitor acute inflammation or tissue injury. 
  Several studies showed that measurement of hs_CRP either 
at admission or at discharge in patients of acute coronary syndrome 
have prognostic value.  Liuzzo et al showed that patients with 
severe unstable angina in absence of myocardial necrosis (proved 
by absence of cTnT, cTnI), hs_CRP concentration >3mg/L) at 
admission were associated with increased incidence of recurrent 
angina, coronary revascularization, MI, and cardiovascular death 
(CVD).Some groups later demonstrated that hs_CRP >3mg/L at 
discharge in 53 patients of unstable angina (UA) was associated 
with increased readmission for recurrent ischemia and MI. 
     Thrombolysis in Myocardial Infarction (TIMI 11A) study 
demonstrated that in UA & Non ST elevation MI (NSTEMI) 
patients markedly increased hs_CRP at presentation in 437 patients 
was a good predictor of 14 days mortality. Furthermore, hs-CRP 
helps to identify those patients with negative cTnT (qualitative 
rapid bed test with cut-off <0.2μgm/L) who were at increased risk 
of mortality. Recent study by De Winter et al showed that hs_CRP 
> 5mg/L at admission in 150 patients with acute coronary 
syndrome were associated with an increased incidence of major 
cardiac events within 6 month regardless of cTnI values.CRP is an 
appropriate marker because it has long half life, remain stable over 
time without any circadian rhythm and fasting blood samples is not 
required. 
 
 
hs- CRP: Angina Pectoris30: 
 
  CRP level correlates with clinical severity of CAD and coronary 
events in both acute and sub acute phases of myocardial ischemia. 
UA patients who are hospitalized, whose hs_CRP > 0.3mg/L have 
more ischemic events in hospital than patients with lower CRP 
levels.CRP levels are significantly lower in patients with stable 
angina than in those with UA or MI. In patients with UA, elevated 
hs_CRP is strong predictor of plaque instability. 
 
     Bazzino31 et al compared the prognostic value of stress test and 
CRP after medical   stabilization of UA and it showed that elevated 
CRP levels were associated with adverse events, when compared 
with stress testing. CRP levels have high sensitivity and specificity. 
Moreover an elevated hs_CRP level at the time of hospital 
discharge appears to be a more sensitive and specific test marker 
for increased risk than a positive stress test. Higher hs_CRP levels 
are strong predictor of recurrent cardiac events whereas low CRP 
levels suggest a good out- come. 
 
 
 
hs- CRP: Predictor of Future Cardiovascular Events32 
     Several prospective studies have demonstrated that hs_CRP is a 
predictor of future cardiovascular morbidity and mortality among 
individuals with known cardiovascular disease. Data from the 
European Concerted Action on Thrombosis and Disabilities 
(ECAT)33 Angina Pectoris Study Group, a study of 2121 men and 
women with stable and unstable angina, demonstrated that each 
standard deviation increase in hs_CRP was associated with a 45% 
increase in the relative risk (RR) of nonfatal MI or sudden cardiac 
death. 
The Cholesterol and Recurrent Events (CARE)34 trial, 
hs_CRP was a predictor of recurrent coronary events in men and 
women who had already suffered a MI. Those with hs_CRP 
concentrations in the highest quintile had an 80% higher chance of 
developing another coronary event within the 5-year study period. 
Therefore, hs- CRP has the potential to be used in the stratification 
of patients into high- and low-risk groups. Perhaps of greater 
clinical importance is the demonstration that hs_CRP 
concentrations predict first MI and stroke. To date, 10 prospective 
studies, 6 in the US and 4 in Europe, have consistently shown that 
hs- CRP is a powerful predictor of future first coronary event in 
apparently healthy men and women. 
     
         Multiple Risk Factors Intervention Trial (MRFIT) 
35demonstrated a direct positive association between hs- CRP and 
CHD mortality in men followed over a 17-yearPeriod. This 
relationship, however, was evident only among smokers. A similar 
association between hs_CRP and future coronary events was noted 
in the Cardiovascular Health Study and Rural Health Promotion 
Project, which included men and women over 65 years of age with 
sub clinical cardiovascular disease36.  
The Physicians’ Health Study (PHS) demonstrated   similar 
positive association between hs_CRP and future coronary events in 
apparently healthy men37. Unlike the observation in MRFIT, 
however, this association was evident in both smokers and 
nonsmokers. This study showed that those in the highest quartile of 
hs_CRP had a twofold higher risk of future stroke, threefold higher 
risk of future MI and fourfold higher risk of future peripheral 
vascular disease The European MONICA (Monitoring Trends and  
Determinants in Cardiovascular Disease) Augsburg study showed 
that an increase of one standard deviation in the log-transformed 
value of hs_CRP was associated with a 50% increase in coronary 
risk and that subjects with hs_CRP concentrations in the highest 
quintile had a 2.6-fold higher risk of developing future coronary 
events38.  
The Women’s Health Study (WHS) showed that hs_CRP is a 
strong predictor of future cardiovascular events in women39. In 
stratified analyses, hs_CRP continued to be a strong predictor of 
future cardiovascular events even among subgroups of women with 
no history of hyperlipidemia, hypertension, smoking, diabetes, or 
family history of CHD40. The hs- CRP concentrations seen in these 
postmenopausal women were somewhat higher than those reported 
previously in men.  
  
EFFECT OF ASPIRIN AND STATIN ON hs_CRP LEVEL 
Although “Statins” lower levels of atherogenic lipids  and 
induce regression of atherosclerotic lesion, other actions beside of 
lipid metabolism may account for some beneficial effects like: 
* It suppresses the expression of adhesion molecule on 
endothelium. 
* Decreases production of metalloproteinases by macrophage that 
allows plaque rapture. 
* Alter macrophage content within the plaque. 
So it is believed that “Statins” have anti-inflammatory effects 
on blood vessel walls.Statins also reduce CRP levels. Pravastatin 
Inflammation / CRP Evaluation Trial41  showed that Pravastatin 
reduced CRP levels at 12 and 24 weeks independent of LDL-C. 
Five year randomized trial of lovastatin for primary prevention of 
coronary events showed that42, lovastatin therapy reduced CRP by 
14.8% and decreased cardiac events in patients with CAD.  
 
Aspirin has cardioprotective effects in patients with CAD. 
Recent study suggested that beside antithrombotic effect it has 
some immunological effects that modulate vascular inflammation. 
Ridker and colleagues first reported that aspirin reduces vascular 
risk (MI, ischemic events) in apparently healthy men in those with 
highest level of hs_CRP. Ikonomidis et al44 also demonstrated that 
aspirin reduces circulating levels of CRP and atherogenic cytokines 
macrophage colony stimulating factors and IL-6 in CAD patients. 
Kennon et al45 also showed that aspirin lowered hs_CRP level in 
patients who are hospitalized with acute coronary syndrome. These 
data suggest that novel approaches to modulating atherosclerosis 
may be provided by cyclooxygenase-2 inhibitors and statin as well 
as by other evolving and novel therapy that target inflammatory 
cascade. 
 
The conclusion of the AHA/CDC report is that high-
sensitivity CRP is probably the best supported inflammatory 
marker. Results less than 1.0 mg per dL represent low risk; 1.0 to 
3.0 mg per L average risk; and greater than 3.0 mg per L, high risk. 
Results greater than 10 mg per L may represent a chronic 
inflammatory or infectious process. Measurements of hs_CRP may 
be useful to identify patients without known cardiovascular disease 
who may be at higher risk than is estimated by major risk factors 
and patients at intermediate risk who require further evaluation or 
therapy, and to motivate moderator high-risk patients to improve 
their lifestyles 
 
 
 
 
The Clopidogrel in Unstable Angina to Prevent Recurrent 
Events Trial demonstrated that combination therapy with aspirin 
(75 to 325 mg/day) and clopidogrel was more effective than aspirin 
alone in preventing cardiovascular events, combination therapy, 
especially may be considered in the patients with CAD and 
elevated hs_CRP levels. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
STUDY DESIGN 
     This study is a single centre prospective analytical study carried 
out in the Institute Of Internal Medicine, Madras Medical College 
during the period of January 2006 to August 2007. Total numbers 
of patients were 75. All the patients in this study were hospitalized, 
no out patients were included .Patients were admitted in Medical 
Wards and Intensive Medical Care Unit .A detailed informed 
consent was obtained from the patients. Our institution`s ethical 
committee clearance was obtained. Standard approved protocol was 
used for treating all the patients. 
INCLUSION AND EXCLUSION CRITERIA 
    Patients of both younger and older age groups were included. 
Inclusion Criteria on   admission were patients admitted with 
angina pectoris or equivalent type of ischemic Discomfort with at 
least one of the features  
1) Rest pain lasting for more than 20 minutes (if not interrupted by 
Treatment) 
2) Severe chest pain of new onset  
3) Chest pain occurring in crescendo pattern (more severe, 
prolonged and more       than previously) with ST/T segment 
changes suggestive of ischemia. 
 
 
Patients were excluded if  
 
• Interval of more than 24 hours of occurrence of pain before 
hospitalization,  
• Presence of ST segment elevation at the time of admission , 
• H/O documented myocardial infarction within pervious 2 
months , 
• Elevated CPK MB isoform on admission , 
•  Intercurrent inflammatory or neoplastic conditions likely to 
be associated, with acute phase response by clinical 
examination and history,  
• Surgery or major trauma in previous month, 
• Having known thrombotic or bleeding disorder, 
• Presence of acute rheumatic fever , collagen vascular 
disorder,degnarative disease ., 
• Patient already taking drugs like statins etc which decreases 
the level of hs_CRP  
 
 
 
 
 
 
STUDY PROTOCOL AND LABORATORY 
INVESTIGATIONS 
    Preliminary history with detail questioning regarding  
1. Chest pain  and angina equivalent, its character ,duration 
,severity and frequency of angina, 
2. Symptoms suggestive of heart failure like breathing 
difficulty ,dyspnea on exertion, PND, orthopnea etc., 
3. Risk factors like h/o smoking and alcoholism for 
considerable period of time, type II DM ,systemic 
hypertension and women in post menopausal group(PML) 
and  
4. Past history and Previous treatment details were taken 
followed by physical examination    
 
A sample of 3cc blood was drawn by venipuncture and 
transferred to dry plain bottle and sent for the analysis of  the 
inflammatory marker of our study highly sensitive CRP ( 
hs_CRP ). The method used for analysis is fully automated 
Nephlometry called BN 100- Nephlometry. 
 
 
 
 The principal of BN 100- Nephlometry46 
 This ultra-sensitive immunoturbidimetric assay uses the method 
called particle- enhanced immunonephlometry to quantitate hs_CRP in 
serum .Polystyrene particles coated with monoclonal antibodies against CRP 
become agglutinated when mixed wit samples containing CRP.The 
intensities of light scattering by  agglutination is measured by nephlometry 
and is directly related to CRP. The assay has sensitivity of 0.1 mg/litre. The 
ready-to-use liquid reagents can be placed directly on a chemistry analyser 
and will yield precise results in minutes (Cortlandt Manor, NY, USA).  
Other Routine blood investigations such as 
1. Complete blood count which includes 
Hb,TC,DC,ESR,Platelet count,  
2. Blood sugar, urea,  
3. Serum creatinine, electrolyte, serum creatinine kinase 
–MB isoform, and  
4. Fasting lipid profile were obtained. 
 
 
The standard 12 leads conventional Electrocardiograph 
(ECG) was taken at the time of admission and analysed for the ST 
Depression (STD) which is suggestive of ischemia. 
 
FOLLOWUP: 
All the patients were followed up for the period of 7 days. 
Everyday details about the severity of angina and its equivalent, 
duration, number of episodes, were noted.  
Routine physical examination and ECG was taken both in the  
morning and in the evening and additional investigations were 
taken if needed.  
TWO DIMENSIONAL TRASNSTHORACIC 
ECHOCARDIOGRAPHY   was taken for the all the patient at the 
time of discharge and their cardiac function and ejection fraction 
was accessed. 
Patients were discharged on 8th day if they were stable 
without any additional ischemic episodes or complication otherwise 
their hospitalization were prolonged. 
 Standard guidelines for the treatment of unstable angina by 
American heart association were followed. The treatment modified 
according to the complications during the hospital stay.                                          
 
 
OBSERVATIONS 
AGE AND hs-CRP 
 
Age Frequency Percentage 
Mean hs-
CRP(mg/dl) SD 
<40 16 21.33 1.84 2.01 
41-50 15 20 2.62 2.02 
51-60 23 30.67 3.67 2.38 
>60 21 28 4.5 1.72 
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SEX AND hs-CRP 
Sex Frequency Percentage Mean hs-CRP(mg/dl) SD 
Male 47 62.7 2.65 2.25 
Female 28 37.33 2.54 2.46 
 
 
0
5
10
15
20
25
30
35
40
45
50
frequency MeanHS_CRP
male
female
 
SEX 
 
Braunwald Class and hs-CRP 
 
 
Braunwald class. Frequency Percentage Mean hs-CRP(mg/dl) 
I B 11 14.67 0.42 
II B 31 41.33 1.51 
III B 33 44 4.37 
 
‘p’ value of <0.001 
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Risk Factors and hs-CRP 
 
RISK 
FACTORS Frequency Percentage
Mean hs-
CRP(mg/dl) SD 
 
P VALUE 
 
Alcoholism 
 
 
5 6.67 2.36 2.84 0.807 
 
Hypertension 
 
 
19 25.33 3.6 2.48 0.030 
 
Type II DM 
 
 
31 41.33 4.76 2.31 <0.001 
 
Smoking 
 
 
19 25.33 3.78 2.72 0.020   
 
Obesity 
 
 
17 22.67 3.05 2.51 0.030 
 
PML 
 
 
17 22.67 3.48 2.64 0.079 
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Severity of Pain and hs-CRP 
 
Severity of pain Frequency Percentage Mean hs-CRP(mg/dl) SD 
Mild 36 48 1.62 1.92 
Moderate 28 37.33 3.18 2.36 
Severe 11 14.67 4.38 1.96 
‘P’ value of <0.001 
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SEVERITY OF PAIN 
 
No of Episodes of Chest Pain and hs-CRP 
Episodes Frequency Percentage Mean hs-CRP(mg/dl) SD 
1 29 38.67 2.54 2.06 
2 22 29.33 1.62 1.92 
3 17 22.67 3.18 3.06 
4 7 9.33 3.08 3.02 
‘P’ value of 0.02 
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NO. OF EPISODE OF CHEST PAIN 
Duration of Chest Pain and hs-CRP 
Duration of chest 
pain Frequency Percentage 
Mean hs-
CRP(mg/dl) SD 
< 30 min 21 28 1.9 2.07 
30-60 min 35 46.7 3.83 2.38 
>60 min 19 25.3 4.8 1.72 
P’ value of <0.001 
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DURATION OF CHEST PAIN 
 
Heart Failure and hs-CRP 
Heart failure Frequency Percentage Mean hs-CRP(mg/dl) SD 
Present 15 20 5.07 1.88 
Absent 60 80 1.99 1.99 
‘p’ value of <0.001 
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HEART FAILURE 
 
 
 
ECHOCARDIOGRAPHY and hs-CRP 
Echo Frequency Percentage Mean hs-CRP(mg/dl) SD 
Normal 49 65.33 1.9 2.07 
Mild LV Dys. 3 4.6 2.5 2 
Moderate LV Dys 16 21.33 3.83 2.38 
Severe LV Dys 7 9.33 4.8 1.72 
P value < 0.001 
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ECHOCARDIOGRAPH 
 
hs-crp Frequency Percentage 
<1 32 42.67
1-4 20 26.67
>4 23 30.67
 
 
DEVELOPMENT OF ARRTHYMIAS  
RBBB VPC LAHB LBBB II BLOCK SINUS BRADY SVT 
TYPES  
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ARRTHYMIAS AND hs-CRP 
ARRTYMIAS FREQUENCY Mean hs-CRP(mg/dl) SD 
Present 28 5.07 1.88 
Absent 47 1.99 1.99 
 
 
 
 
 
ECG CHANGES AND hs_CRP 
 
ECG PERCENTAGE Mean hs-CRP(mg/dl) 
LWI 13.33 3.14 
ILI 16 2.55 
ASI 21.33 3.04 
IWI 24 2.02 
AII 13.33 1.87 
AWI 12 3.31 
 
LWI- LATERAL WALL ISCHAEMIA 
ILI – INFEROLATERAL WALL ISCHAEMIA 
ASI – ANTERO SEPTAL ISCHAEMIA 
IWI – INFERIOR WALL ISCHAEMIA 
AII –ANTEROINFERIOR WALL ISCHAEMIA 
AWI –ANTERIOR WALL ISCHAEMIA 
 
 
DISCUSSION 
Total number of patients included in this study were 75. 
Variables that were analysed in this study were age, sex, and 
severity of angina, no. of episodes of angina per day, duration of 
each anginal episode, development of heart failure, arrhythmias and 
risk factors of cardiovascular disease.  This study compares these 
variables with the level of hs_CRP in the serum. In this study, mean 
value of hs_CRP were found to be 2.61 mg/dl. 
 
AGE 
Of the 75 patients, 16 patients were in age group less than 40 
years, 15 patients were between 41-50 years, 23 patients were 
between 51-60 years, and 21 patients were more than 60 years. The 
mean hs_CRP level in each group were 1.84, 2.62, 3.67and 4.50 
mg/dl respectively . Thus there is gradual increase in hs_CRP levels 
with increasing age. 
 
This correlate with previous study by M.A. Mendell et al, 
Praful patel et al, that there is an elevation of hs_CRP level with 
increasing age. Another study by Seishi Yamada et al in Japanese 
population also confirms this observation. In the study by Naomi et 
al that in elderly patient there is increase in hs_CRP level which in 
turn increases the production of tissue factors by monocytes. The 
monocytes titer factor production is increased by several folds in 
elderly patients. This titer factor is responsible for activation of 
extensive coagulation cascade leading to thrombus formation and 
acute coronary events in elderly population. These elevations of 
hs_CRP in postmenopausal women were more than that of men in 
the similar age group. 
 
SEX 
In this study, number of male patients were 47 (62.67%) 
while no number of female patients were 28 (37.23), and their 
average hs_CRP were  2.65  and 2.54 mg/dl respectively.  
 
In previous study Nakagomi et al showed that CRP level 
were more in men comparing with women in younger age group 
(<50 yrs) but as the age advances the CRP level gradually rises and 
at post menopausal age that CRP level were significant greater than 
the CRP values in men of similar age group. Also there is gross 
increase in CRP levels in younger women (<50 yrs) comparing to 
post menopausal women also noted in this study. The same 
observations were also seen in other studies conducted by M.A. 
Mendall et al and Yamada et al.  But in women Health Study 
(WHS) states that although no difference in hs_CRP values was 
noted between premenopausal women and age-matched males, 
recent reports showed that hormone replacement therapy (estrogen 
alone or estrogen and progestin) is associated with increased 
hs_CRP concentrations. These findings suggest that the increased 
hs_CRP seen in the WHS subjects may reflect the influence of 
hormone replacement therapy rather than the effect of gender. In 
our study no significant difference is noted between two sexes. 
 
Braunwald classification: 
 
This classification was proposed to assess the severity and 
risk stratification in unstable Angina. In this study out of total 
number cases, 11 patients were classified under class IB, 31 
patients under class IIB and 33 patients were under class IIIB and 
their mean hs_CRP value were 0.42, 1.51, and 4.37 mg/dl 
respectively with ‘p’ value of <0.001 which denotes significant at 
1% level which implies there is significant increase in the level of 
hs-CRP over progressing Braunwald classes from IB to IIIB. 
In a study by Ferreiros, Boissonet CP et al where 194 
patients were studiedand found to have elevation of hs-CRP levels 
which increased over progressing Braunwald classes from IB to 
IIIB and in this study Braunwald class C patients were not included 
because in post infarction angina of less than 2 weeks duration 
there may be a confounding factor in CRP elevation due to 
myocardial necrosis and it takes for minimum of 4 weeks for CRP 
values to come to normal after an acute myocardial infarction. In 
our study also Braunwald Class C patients were not included for 
same reason. 
Coronary Risk factors: 
 Risk factors that were present in the study group were 
smoking, alcohol, hypertension, diabetes, post menopausal age 
group and obesity. Several CHD risk factors appear to modulate the 
inflammatory response and affect hs_CRP concentration. 
Of the total number of patients, 19 patients had history of 
smoking for considerable period of time. Of these patients, the 
mean hs_CRP was 3.76 mg/dl  when compared  to those without 
the history of smoking was 2.06 mg/dl with ‘p’ value 0.020  which 
denotes significant at 5% level. 
Cigarette smoking has also been shown to increase the 
concentration of several inflammatory markers, including hs_CRP, 
interleukin-6, and soluble intercellular adhesion molecule-1. 
Increases of both interleukin-6 (Ridker PM et al) and soluble 
intracellular adhesion molecule-1 were shown to be associated with 
increased risk of future first coronary events in both men and 
women. Smoking cessation decreases these markers. 
Of the total number of patients,the history of alcohol intake 
for significant period of time were found in 5 patients and their 
mean hs_CRP value was 2.84 mg/dl when compared to those who 
were not in the habit of taking alcohol is 2.30 mg/dl with ‘p’ value 
0.807 which indicates statistically not significant. These were no 
previous study that assessed the level of hs-CRP and alcohol intake. 
Of the total number of patients, 17 patients were found to be 
obese by means of BMI and their mean hs_CRP value was 3.65 
mg/dl when compared to those who were not obese with their mean 
hs_CRP value was 2.08 ,with ‘P’ value of 0.030 which denotes 
significant at 5% levels.  
Obesity, for example, is directly associated with increased 
hs_CRP concentrations, an intriguing observation considering that 
interleukin-6, the primary stimulant of the de novo hepatic 
synthesis of CRP, is secreted by adipose tissue (Visser M, Bouter 
LM, McQuillan GM, Wener MH, Harris TB et al). Therefore, the 
attenuation of the inflammatory response may represent a 
mechanism by which diet and weight loss reduces cardiovascular 
risk. 
Of the total no. of patients, 19 patients had h/0 hypertension 
on treatment, and their mean hs_CRP value were 3.60 mg/dl when 
compared to those without hypertension was 2.27mg/dl, with ‘P’ 
value of 0.030 which denotes significant at 5% levels. This value 
significantly correlates with other studies. 
Laurie G. Futterman et al : Hypertension may be linked to 
inflammation by angiotensin II. In addition to its vaso-constricting 
properties, angiotensin II can trigger intimal inflammation which 
leads to raise of hs-hs_CRP and the patient admitted with 
hypertension and unstable angina with high level of hs-hs_CRP 
were at high risk.  
In this study group, 31 patients had Type 2 diabetes mellitus 
with their mean hs_CRP was 4.76 mg/dl when compared to 
1.50mg/dl in non-diabetic patients group with ‘P’ value is <0.001 
which denotes significant at 1% level. 
Diabetic patients are reported to have increased hs_CRP 
values (Ford ES et al  ); In this regard, links between hs_CRP and 
the insulin resistance syndrome have also been reported (Yudkein 
et al). In addition, experimental findings suggest that increased 
blood pressure promotes endothelial expression of cytokines and 
inflammatory activation. These observations suggest that perhaps 
better control of diabetes and hypertension may attenuate the 
contribution of the inflammatory response to overall cardiovascular 
risk. Taken together, the available evidence thus supports the 
hypothesis that hs_CRP concentrations correlate with endothelial 
dysfunction  
Analysis of Anginal Episodes: 
Regarding the average number of angina episodes per day in the 
study group, single episode was present in 29 patients with their 
mean hs_CRP 2.54 mg/dl, two episodes were present in 17 patients 
with their mean hs_CRP 3.18 mg/dl, and 4 episodes were present in 
7 patients with their mean hs_CRP 3.08 mg/dl. Thus there is a 
progressive increase in hs-CRP levels with increase in number of 
anginal episodes with ‘P’ value of 0.02 which denotes significant at 
5% levels. 
Liuzzo et al. showed that in 31 patients with severe unstable 
angina and no evidence of myocardial necrosis, as documented by 
the absence of increased cardiac troponin T, hs_CRP concentrations 
>3 mg/L at admission were associated with an increased incidence 
of recurrent angina, coronary revascularization, MI, and 
cardiovascular death. The same group later demonstrated that 
hs_CRP >3 mg/L at discharge in 53 unstable angina patients was 
associated with increased readmission for recurrent instability and 
MI. In a similar study of unstable angina, Ferreiros et al. concluded 
that the prognostic value of hs_CRP measured at discharge was 
better than that determined at admission in predicting adverse 
outcome at 90 days.  
Furthermore, hs_CRP was the strongest independent 
predictor of adverse events in multivariate analysis. Data from the 
Thrombolysis In Myocardial Infarction 11A (TIMI 11A), a study of 
unstable angina and non-Q-wave MI, showed that markedly 
increased hs_CRP (15.5 mg/L) at presentation in 437 patients was a 
good predictor of 14-day mortality in that population. Furthermore, 
hs_CRP helped to identify those patients with negative cardiac 
troponin T (qualitative rapid bedside method with cutoff of <0.2 
µg/L) who were at increased risk of mortality .A recent report by de 
Winter et al showed that hs_CRP concentrations >5 mg/L at 
admission in 150 patients with non-ST-elevation acute coronary 
syndromes were associated with an increased incidence of major 
cardiac events within 6 months, regardless of cardiac troponin I 
values.  
Duration and severity of angina 
Regarding average duration of Anginal episodes, 21 patients 
had chest pain for < ½ hr with their mean hs_CRP 1.90mg/dl, 35 
patients had for ½ -1 hr with their mean hs_CRP 3.83 mg/dl ,19 
patients had for >1 hr with their mean hs_CRP 4.80 mg/dl. This 
shows that there is an increase in hs_CRP value with increase in 
duration of each episode with ‘P’ value of <0.001, which denotes 
significant at 1% level. 
Regarding of severity of Angina which is a subjective 
variable 36 patients had mild anginal episodes with their mean 
hs_CRP was 1.62 mg/dl, 28 patients with moderate anginal 
episodes with their mean hs_CRP 3.18 mg/dl, 11 patients with 
severe anginal episodes with their mean 4.38 mg/dl. Thus in this 
study there was steady increase in hs-CRP levels with increase in 
severity of Anginal episodes with the ‘P’ value of <0.001 which 
indicates significant at 1% level. 
 In the study by Giovanna Liuzzo et al where prognostic 
value of CRP was studied. The patient with low hs_CRP elevation 
was discharged sooner from hospital had only few anginal episodes 
and most of which were silent and duration was minimal. In 
patients  with high hs_CRP value has more number of ischemic 
episodes and signs of ischemic were significantly longer and they 
may need coronary intervention. Similar study by MP Holay et al 
states that high hs-CRP was associated with increased severity, 
duration, and number of episodes. This elevated hs-CRP values 
may be used for risk stratification of patients with unstable angina 
who need urgent coronary revascularization procedure. In a study 
by Biasucci et al who showed elevated CRP at discharge may 
associated with recurrent instability of Angina. 
 
In another study by Liuzzo CRP levels a raised in patients 
who were undergoing coronary Angioplasty and severe unstable 
Angina. The elevation of CRP values in proportion to increase in 
frequency of Anginal  episodes, severity of anginal episodes and 
duration of each anginal episodes may reflect the severity of 
inflammation that is taking place is eroded or ruptured plaque on 
the vessel wall loading to thrombus formation and progression. The 
elevation of CRP may not be due to myocardial necrosis because 
the Troponin values in this study were within normal range. 
 
 
 
 
ECG CHANGES 
 
Out of 75 patients, the type of the regional wall ischemia and 
their frequency are narrated in the tabular column and there is no 
considerable remarks to the level hs_CRP and the area of ischemia. 
 
Liao Y, Liu K, Dyer A, et al assesses the combined high-
sensitivity CRP and ECG STD (ST Depression) criteria.   Because 
CRP and STD criteria provided independent prognostic 
information, the ability of the combination of these variables to 
improve prediction of mortality was assessed. In Cox analyses 
stratified by study center, the combined CRP and ECG STD 
variable improved risk stratification compared to either CRP or 
STD alone for both CVD and all-cause mortality, with the presence 
of both ECG STD and an elevated CRP associated with the greatest 
risks 
 
 
 
 
 
Arrhythmias: 
  Out of 75 patients, 28 patients developed some form of 
arrhythmias as indicated in tabular column with ECG changes. 
Winter et al showed those patient admitted with high level of 
serum hs_CRP were prone to develop some form of Arrhythmias 
and more prone for sudden cardiac death. 
 
 
Heart Failure and Echocardiography abnormality 
Of the total number of patients, 15 patients developed heart 
failure during the hospital stay with their mean hs_CRP was 5.0 
mg/dl when compared to those without heart failure of hs_CRP 
1.99 mg/dl with ‘p’ value of <0.001 which denotes significant as 
1% level . 
Of the total number of cases, 49 patients had normal LV 
function with their mean hs-CRP 1.90 mg/dl, 3 patients had mild 
LV dysfunction with their mean hs_CRP 2.50 mg/dl, 10 patients 
had moderate LV dysfunction with their mean hs_CRP 3.83 mg/dl, 
7 patients had severe LV dysfunction with their mean hs_CRP 4.80 
mg/dl. Thus there is steady increased hs_CRP value as severities of 
LV dysfunction increased with ‘P’ value <0.001 which denotes 
significant at 1% level. 
Suleiman et al showed that plasma hs_CRP level is an 
independent marker of development of heart failure in patients with 
acute coronary syndrome .CRP levels may be related to 
inflammatory process associated with ischemic expansion and 
ventricular remodeling. Berton et al the first day hs_CRP level is 
the strongest predictor of both heart failure and depressed LV 
function. 
 This study carried out in 75 patients with unstable angina 
predicting the role of the elevated hs-CRP in the occurrence of 
minor and major coronary events during the hospital (average 7 
days) and also the occurrence of complication in those 
patrients.The results of this study strongly correlates with hs-CRP 
elevation and the occurrence  of minor and major coronary events 
and also the occurrence of complications .These findings correlates 
with results of other studies. 
  
The hs- CRP level not only predicts the patient outcome in 
the hospital stay (short term) but also prognostic outcome and 
mortality in 1 month,3 months and 2 years in various studies 
carried out. 
 
The hs- CRP level if combined with Trop-T, fibrinogen 
levels additionally predicts the prognostic outcome with greater 
sensitivity and specificity . The levels should be determined as 
early as possible after admission. 
 
Should we include hs- CRP in the risk profile? 
       Based on solid and consistent evidence, the Centre for Disease 
Control and Prevention and the American Heart Association issued 
a recommendation for the screening of hs-CRP as a routine part of 
global cardiovascular risk assement and the determination of hs-
CRP should be done at least done at baseline. 
 
 
hs-CRP ,a modifiable risk factor? 
There are increasing evidence that decrease in hs- CRP were 
associated with decreasing coronary events and progression of 
atherosclerosis. The addition of Aspirin and Statins to the therapy 
modifies the inflammation and decrease the hs- CRP levels. Also 
evidenced that Statins possess the properties beyond the lipid 
lowering effects  , include anti-inflammatory effects which seems 
to be independent of their antilipaemic effect. 
 
 
 
 
 SUMMARY: 
hs_CRP estimation was done for 75 patients of Unstable 
Angina admitted in the medical ward of Institute Of Internal 
Medicine ,Madras Medical College Hospital following observation 
was made. 
¾ hs_CRP level in unstable Angina patients strongly correlates 
with number, duration and severity of Anginal episodes. 
¾ hs-CRP level strongly correlates with development of other 
complications such as development of heart failure, 
arrhythmias, left ventricular dysfunction. 
¾ hs_CRP level is increased in smoker, obesity, diabetes, 
hypertension, family history, post meno pausal women 
comparing to those without these risk factors. 
¾ hs_CRP level also increasing with advancing age  
¾ hs_CRP level progressively increased in patients from IB to 
IIIB in Braunwald classification. 
 
 
CONCLUSION 
   Our understanding of atherosclerosis has evolved beyond the 
view that these lesions consist of a lifeless collection of lipid debris. 
Current evidence supports a central role for   inflammation in all 
phases of the atherosclerotic process. Substantial biological data 
implicate inflammatory pathways in early atherogenesis, in the 
progression of lesions, and finally in the thrombotic complications 
of this disease. Clinical studies affirm correlation of  hs_CRP is the 
novel and evolving biomarker of inflammation with propensity to 
develop ischemic events and with prognosis after ACS. 
Intralesional or extralesional inflammation may hasten atheroma 
evolution and precipitate acute events. Hs_CRP  elicited by 
inflammation may not only mark increased risk for vascular events, 
but in some cases may contribute to their pathogenesis. This new 
insight into the role of inflammation in the pathobiology of 
atherosclerosis has initiated important new areas of direct clinical 
relevance. We can use hs_CRP today for risk stratification.  
 
Based on various studies, increased hs_CRP levels inpatients 
with high risk cardiovascular disease without documented CAD 
warrant treatment with statin even if LDL-C levels are within target 
range.  Patients with documented CAD and high hs-hs_CRP levels 
should be followed, and there risk factors should be managed 
aggressively..  
Finally, the quest to identify proximal stimuli for 
inflammation, as one pathogenic process in atherogenesis or trigger 
to lesion complication, may yield novel therapeutic targets in years 
to come.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Sl. 
NO. Age 
Braunwald 
classification 
Angina  
equivalent Risk factors 
Previous 
H/O 
CAD 
Angina 
episodes 
/ day 
Duration 
of each 
episode 
Severity 
of Angina Arrythmias 
Heart 
failure MI E
1. 45/F II B Angina DM / 
SHT  
Nil One 240 min Moderate NO NO NO L
2. 40/M III B Angina Smoker  CSA 
2 Yrs. 
Three 240 min Severe RBBB NO NO 
3. 50/F I B Angina Nil Nil One 30 min Mild NO NO NO 
4. 40/F II B Angina DM  Nil One 60 min Mild NO NO NO A
5. 48/M II B Angina DM CSA 2 
yrs 
Three 60 min Moderate NO NO NO IW
6. 35/F II B Angina Obese Nil Four 120 min Moderate NO NO NO A
7. 54/M III B Angina 
/Syncope 
DM /SHT  ASMI 5 
yrs 
before 
Three 120 min Severe VPC YES NO AS
8. 58/M III B Angina/ 
Palpitation 
Smoker/ 
Alcoholic  
CSA  
1 Yr 
Two 240 min Severe NO NO NO A
9. 40/M II B Angina SHT  Nil Single 60 min Mild NO NO NO A
10. 54/M III B Angina SHT/obese CSA 2 
yrs 
Four 240 min Severe NO NO NO IW
11. 55/M II B Angina/ 
Epigastric 
pain 
Alcoholic / 
DM  
Nil Four 30 min Moderate NO NO NO IW
12. 50/M I B Angina  NO One 30 min Mild NO NO NO A
13. 50/F II B Angina DM  ASMI 5 
yrs 
One 60 min Mild NO YES NO IW
14. 55/M I B Angina Smoker/DM CSA Two 60 min Mild NO NO NO A
15. 75/M II B Angina 
Dys. IV 
SHT  CSA 
TMT 
YESve 
One 20 min Moderate NO NO NO A
16. 55/M III B Angina 
Dyspnea  
C IV 
Smoker AWMI  
2 yrs 
Three 30 min Moderate LBBB YES NO A
17. 40/F I B Angina DM  NO Two 20 min Mild NO NO NO A
18. 65/M III B Angina/ 
Syncope 
DM /SHT AWMI 2 
yrs 
Three 60 min Moderate VPC NO NO IW
19. 70/M III B Angina 
Dysp. C IV 
DM /SHT  HA Two 20 min Moderate LAHB YES NO IW
Sl. 
NO. Age 
Braunwald 
classification 
Angina  
equivalent Risk factors 
Previous 
H/O 
CAD 
Angina 
episodes 
/ day 
Duration 
of each 
episode 
Severity 
of Angina Arrythmias 
Heart 
failure MI E
20. 60/M II B Angina 
Syncope 
Smoker/ 
Alcoholic 
NO Three 30 min Mild NO NO NO 
21. 50/F II B Angina 
Syncope 
DM  NO Two 120 min Mild NO NO NO IW
22. 40/F I B Angina DM  CSA 
TMT 
YESve 
Two 120 min Mild NO NO NO A
23. 48/F III B Angina 
Syncope 
SHT/DM NO Four 60 min Moderate RBBB NO NO I
24. 60/M III B Angina Smoker Nil Four 60 min Mild NO NO NO A
25. 48/M II B Angina NO NO One 60 min Mild NO NO NO IW
26. 61/F III B Angina/ 
Dys. C IV 
DM Old MI Three 30 min Moderate LBBB YES NO A
27. 40/M III B Angina Obese NO Three 20 min Moderate LAHB NO NO IW
28. 63/F III B Angina 
Syncope 
PML NO One 20 min Severe NO NO NO A
29. 65/M II B Angina / 
Palpitation 
Smoker / 
Alcoholic 
NO One 60 min Mild NO NO NO A
30. 30/M I B Angina / 
Palpitation 
Smoker NO One 60 min Mild WPW 
Syndrome 
NO NO A
31. 65/M II B Angina / 
Palpitation 
NO NO Two 120 min Moderate First 
degree AV 
block 
NO NO 
32. 30/M III B Angina  DM/SHT CSA 
TMT 
YES 
Three 120 min Severe VPC NO NO 
33. 45/M I B Angina  NO NO Oe 20 Min Mild  NO NO A
34. 25/M III B Angina  Smoker / 
Alcoholic 
CSA 
TMT 
YES 
Two 60 min Severe NO NO NO 
35. 40/F II B Angina  NO NO Two 30 min Moderate NO NO NO A
36. 45/F II B Angina  DM NO Three 40 min Moderate NO NO NO 
37. 59/F III B Angina  
Dys C IV 
DM / SHT/ 
obese 
Old MI 
AWMI 
Four 60 min Severe LBBB YES NO A
38. 64/M II B Angina  DM NO Three 40 min Moderate NO NO NO 
39. 60/M II B Angina / 
Palpitation 
DM / 
Obese  
NO Two 20 min Moderate Sinus 
Brady 
NO NO IW
Sl. 
NO. Age 
Braunwald 
classification 
Angina  
equivalent Risk factors 
Previous 
H/O 
CAD 
Angina 
episodes 
/ day 
Duration 
of each 
episode 
Severity 
of Angina Arrythmias 
Heart 
failure MI E
40. 64/M III B Angina  Smoker  / 
SHT 
CSA  
TMT 
YES 
Four 60 min Moderte NO NO NO A
41. 40/F II B Angina  SHT NO One 20 min Mild NO NO NO IW
42. 82/F I B Angina  NO NO One 10 min Mild NO NO NO IW
43. 56/F II B Angina DM NO Three 30 min Mild NO NO NO A
44. 40/M III B Angina 
/ Dys C IV 
DM / SHT NO Two 40 min Moderate VPC YES NO A
45. 35/M II B Angina Smoker  NO Two 30 min Moderate NO NO NO IW
46. 70/F III B Angina  
/ Dys IV 
DM / SHT CSA Three 20 min Mild LBBB YES NO A
47. 65/M II B Angina DM NO One 30 min Mild NO NO NO L
48. 65/M III B Angina DM / 
Obese 
NO One 20 min Mild NO NO NO 
49. 54/F I B Angina DM / 
Obese 
NO One 20 min Mild NO NO NO 
50. 48/M I B Palpitation  
/ Angina 
Smoker / 
DM 
NO One 30 min Mild SVT NO NO 
51. 42/M II B Angina Obese NO One 60 min. Mild NO NO NO A
52. 58/M III B Angina / 
Dys C. IV 
Smoker NO Two 20 min Moderate LBBB YES NO A
53. 60/M II B Angina 
 
Obese NO One 20 min Mild NO NO NO L
54. 64/M II B Angina / 
Dys C. IV 
Obsese 
/PML 
CS AYES Three 10 min Moderate RBBB YES AIMI A
55. 58/F II B Angina / 
Palpitation 
PML NO Two 30 min Mild NO NO NO IW
56. 58/M II B Angina / 
Syncope 
Nil NO Three 60 min. Moderate NO NO NO IW
57. 40/M III B Palpitation 
/ Angina 
Smoker NO One 20 min Mild SVT NO NO L
58. 70/F III B Angina 
/ Dys IV 
PML AWMI  
2 Yrs. 
Two 20 min Mild VPC YES NO L
59. 70/M III B Angina 
/ Dys IV 
DM/SHT IWMI  
5 Yrs. 
Two 20 min Mild VPC YES NO IW
60. 80/M II B Angina Smoker NO One 30 min Mild NO NO NO IW
Sl. 
NO. Age 
Braunwald 
classification 
Angina  
equivalent Risk factors 
Previous 
H/O 
CAD 
Angina 
episodes 
/ day 
Duration 
of each 
episode 
Severity 
of Angina Arrythmias 
Heart 
failure MI E
61. 64/M I B Angina NO TMT 
YES 
Two 20 min Mild NO NO NO L
62. 52/F II B Angina DM NO One 20 min Mil NO NO NO A
63. 49/F III B Angina 
/Palpitation  
Obese / 
PML 
NO Three 40 min Moderate Sinus 
Brady 
NO NO L
64. 54/M II B Angina DM / SHT NO One 120 min Mild NO NO NO A
65. 55/F III B Angina PML NO Two 120 min Severe LBBB YES NO 
66. 56/M III B Angina 
/ Dys C IV 
Smoker / 
SHT 
NO Two 30 min Moderate VPL NO NO L
67. 70/M III B Angina 
/Palpitation 
NO CSA One 20 min Moderate NO NO NO A
68. 56/F II B Angina 
Syncope 
Obese / 
DM 
NO One 20 min Moderate BI 
Fascicular 
Block 
NO NO A
69. 60/F II B Angina / 
Palpitattion 
PML / 
Obese 
CSA Two 20 min Mild NO NO NO 
70. 45/M III B Angina / 
Dys 
C IV 
Smoker ASMI  
2 Yrs. 
One 30 min Severe VPC 
LAHB 
YES NO A
71. 40/M III B Angina  Smoker NO One 30 min Moderate SVT NO NO A
72. 64/M III B Angina  DM / SHT CSA Two 40 min Mild NO NO NO A
73. 42/M III B Angina  / 
Palpitation 
Smoker NO Two 40 min Moderate VPC NO AWMI IW
74. 60/F III B Angina   NO NO One 40 min Mild NO NO NO 
75. 58/F III B Angina   
Dys. C IV 
DM/ SHT/  
Obese 
AWMI 
6 Yrs. 
Three 120 min Severe LBBB YES NO A
SHT- systemic hypertension               DM-Diabetes mellitus                      Obe-Obesity                     
SM-Smokers 
LWI- lateral wall ischemia                            VPC-Ventricular premature complex          
PML-Postmenopausal          ASI – antero septal ischemia                           
ILI – inferolateral wall ischemia                    SVT-Supraventricular tachycardia             
LBBB-left bundle branch block   C IV-Class IV  
. IWI – inferior wall ischemia                         LAHB-Left anterior hemi 
block               AII –anteroinferior wall ischemia                   
RBBB-Right bundle branch block                 AWI –anterior wall ischemia                      
LV Dysfn.-LV Dysfunction. 
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